IA Announce the Acceptance of 2 Abstracts from Clinical Studies in Rheumatoid and Juvenile Rheumatoid Arthritis at EULAR 2017
Image Analysis Group (IA-Group) announces the acceptance of two abstracts from clinical studies in Rheumatoid and Juvenile Rheumatoid Arthritis by the Annual European Congress of Rheumatology organized by the European League Against Rheumatism (EULAR) 2017, held in Madrid from 14-17 June. To schedule a meeting with the team please email to: firstname.lastname@example.org
Following is a list of accepted abstracts:
“Quantification of Dynamic MRI Examinations in Juvenile Idiopathic Arthritis,” N. Tzaribachev, R. Hagoug, P. Louka, J. Islam, M. Hinton, O. Kubassova, M. Boesen, showing that in 18 patients statistically significant and clinically meaningful changes were documented for Dynamic Contrast Enhanced MR Quantification (DEMRIQ) method. In all patients sub-clinical disease could be detected on MRI in clinically unaffected joints. The abstract will be presented as a poster on 17 June 2017 at 10:15 Poster area / Poster session III.
“Dynamic Contrast Enhanced MRI in Randomised Placebo-Controlled Rheumatoid Arthritis Trial – Impact of Applying Joint Coverage Quality Criteria,” M. B. Axelsen, H. Bliddal, L. T. H. Jacobssen, M. S. Hansen, A. Dudek, M. Rell-Bakalarska, M. Boesen, J. Stefanek, B. Sundman-Engberg, M. Østergaard emphasises the importance of standartization of DCE-MRI as an critical imaging endpoint in efficacy trials
The European League Against Rheumatism (EULAR) is the organization which represents the patient, health professional and scientific societies of rheumatology of all the European nations. EULAR endeavors to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. In line with UEMS, EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems.
About Image Analysis Group
IA-Group is a strategic partner to bio-pharmaceutical companies. We bring extensive expertise in strategic use of clinical imaging to quantitatively assess the efficacy of new drug candidate and to increase the objectivity of early go / no go decisions. We leverage 10 years of expertise in advanced image analysis, global footprint and our proprietary next-generation cloud Imaging Trial Data Management platform Dynamika to accelerate drug development, de-risk trial execution of trials and to ensure integrity and scientific credibility of your data. Our venture arm pioneers unique targeted investment and risk-sharing models to enable our clients to reach the next value inflection point faster. We fuse decades of therapeutic insight and agile culture to meet today’s speed and high standard of therapeutic innovation. E: email@example.com or T: + 44 74 13 02 20 53 / + 1 6177 523561